All In Biotech

Drug Trial Radar · NCT02147158

A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas

A Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate for the Intermittent Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas

Last checked: Nov 20, 2026Latest source record: Jun 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 432 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

432

Actual

Start

Jan 29, 2014

Primary completion

Nov 24, 2016

Study completion Nov 24, 2016

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
May 26, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the superiority of ulipristal acetate versus placebo for the treatment of abnormal uterine bleeding associated with uterine fibroids

Conditions

  • Leiomyoma
  • Uterine Hemorrhage

Interventions

  • Ulipristal acetate (UPA)Drug

    Ulipristal acetate (UPA) tablet.

  • PlaceboDrug

    Matching placebo tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Absence of Bleeding During the Last 35 Consecutive Days on Treatment in Treatment Course 1Time frame: Last 35 consecutive days on treatment in the 12-Week Treatment Course 1
  2. Time to Absence of Bleeding on Treatment During Treatment Course 1Time frame: From first dose up to the end of the 12-Week Treatment Course 1

Locations

63 sites in 2 countries. Site status is shown where the registry gives one.

  • Watson Investigational Site 138

    Mesa, Arizona

  • Watson Investigational Site 147

    Phoenix, Arizona

  • Watson Investigational Site 106

    Scottsdale, Arizona

  • Watson Investigational Site 124

    Tucson, Arizona

  • Watson Investigational Site 155

    Little Rock, Arkansas

  • Watson Investigational Site 155

    Encino, California

  • Watson Investigational Site 157

    Hawaiian Gardens, California

  • Watson Investigational Site 134

    La Mesa, California

  • Watson Investigational Site 127

    San Diego, California

  • Watson Investigational Site 151

    San Diego, California

  • Watson Investigational Site 159

    Denver, Colorado

  • Watson Investigational Site 131

    Clearwater, Florida

  • Watson Investigational Site 135

    Miramar, Florida

  • Watson Investigational Site 132

    North Miami, Florida

  • Watson Investigational Site 161

    Orlando, Florida

  • Watson Investigational Site 123

    Plantation, Florida

  • Watson Investigational Site 112

    Sarasota, Florida

  • Watson Investigational Site 102

    Wellington, Florida

  • Watson Investigational Site 101

    West Palm Beach, Florida

  • Watson Investigational Site 160

    Atlanta, Georgia

  • Watson Investigational Site 103

    Sandy Springs, Georgia

  • Watson Investigational Site 117

    Savannah, Georgia

  • Watson Investigational Site 113

    Champaign, Illinois

  • Watson Investigational Site 119

    Schaumburg, Illinois

  • Watson Investigational Site 162

    Brownsburg, Indiana

  • Watson Investigational Site 104

    Granger, Indiana

  • Watson Investigational Site 150

    Covington, Louisiana

  • Watson Investigational Site 130

    Metairie, Louisiana

  • Watson Investigational Site 116

    New Orleans, Louisiana

  • Watson Investigational Site 108

    Las Vegas, Nevada

  • Watson Investigational Site 107

    Las Vegas, Nevada

  • Watson Investigational Site 111

    Lawrenceville, New Jersey

  • Watson Investigational Site 158

    Moorestown, New Jersey

  • Watson Investigational Site 115

    Albuquerque, New Mexico

  • Watson Investigational Site 155

    The Bronx, New York

  • Watson Investigational Site 126

    Durham, North Carolina

  • Watson Investigational Site 128

    Greensboro, North Carolina

  • Watson Investigational Site 145

    New Bern, North Carolina

  • Watson Investigational Site 146

    Raleigh, North Carolina

  • Watson Investigational Site 118

    Winston-Salem, North Carolina

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.